Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 May 16;10(3):e01182-22. doi: 10.1128/spectrum.01182-22

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Shmidov et al.

This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.

PMC Copyright notice

FIG 6 — The prrA mutants show enhanced fitness in the subinhibitory treatment of aminoglycosides. (A) MIC experiment with Kan antibiotic, with concentrations ranging from 0 to 300 μg/mL. The MIC for Kan in both strains is 198 μg/mL, and the subinhibitory concentration is 131 μg/mL. (B) MIC experiment with Strep antibiotic, with concentrations ranging from 0 to 800 μg/mL. The MIC for Kan in both strains is 400 μg/mL, and the subinhibitory concentration is 200 μg/mL. (C) The growth curve of the different strains with the treatment of Kan in the concentration of 100 μg/mL. (D) The growth curve of the different strains with the treatment of Strep in the concentration of 400 μg/mL. (E) Competition assay for WT and prrA mutant coculture. The y axis represents the percentage of prrA strain in the different treatments. The above graphs are the average of three independent experiments with three replicates each. Error bars represent the standard deviations.